bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figure Legend from A Prospective PCR-Based Screening for the EML4-ALK Oncogene in Non–Small Cell Lung Cancer
Authors: Soda Manabu , Isobe Kazutoshi , Inoue Akira , Maemondo Makoto , Oizumi Satoshi , Fujita Yuka , Gemma Akihiko , Yamashita Yoshihiro , Ueno Toshihide , Takeuchi Kengo , Choi Young Lim , Miyazawa Hitoshi , Tanaka Tomoaki , Hagiwara Koichi , Mano Hiroyuki
Published: April 2023

PDF file, 92K.
Supplementary Figure 5 from A Prospective PCR-Based Screening for the EML4-ALK Oncogene in Non–Small Cell Lung Cancer
Authors: Soda Manabu , Isobe Kazutoshi , Inoue Akira , Maemondo Makoto , Oizumi Satoshi , Fujita Yuka , Gemma Akihiko , Yamashita Yoshihiro , Ueno Toshihide , Takeuchi Kengo , Choi Young Lim , Miyazawa Hitoshi , Tanaka Tomoaki , Hagiwara Koichi , Mano Hiroyuki
Published: April 2023

PDF file, 1269K, Genomic rearrangement responsible for the EML4-ALK fusion gene in J-#927.
Supplementary Figure 3 from A Prospective PCR-Based Screening for the EML4-ALK Oncogene in Non–Small Cell Lung Cancer
Authors: Soda Manabu , Isobe Kazutoshi , Inoue Akira , Maemondo Makoto , Oizumi Satoshi , Fujita Yuka , Gemma Akihiko , Yamashita Yoshihiro , Ueno Toshihide , Takeuchi Kengo , Choi Young Lim , Miyazawa Hitoshi , Tanaka Tomoaki , Hagiwara Koichi , Mano Hiroyuki
Published: April 2023

PDF file, 22605K, cDNA sequence for a novel EML4-ALK variant.
Supplementary Figure 1 from A Prospective PCR-Based Screening for the EML4-ALK Oncogene in Non–Small Cell Lung Cancer
Authors: Soda Manabu , Isobe Kazutoshi , Inoue Akira , Maemondo Makoto , Oizumi Satoshi , Fujita Yuka , Gemma Akihiko , Yamashita Yoshihiro , Ueno Toshihide , Takeuchi Kengo , Choi Young Lim , Miyazawa Hitoshi , Tanaka Tomoaki , Hagiwara Koichi , Mano Hiroyuki
Published: April 2023

PDF file, 2681K, Specimens obtained in our prospective cohort.
Supplementary Table 3 from Mutations in the Ras–Raf Axis Underlie the Prognostic Value of CD133 in Colorectal Cancer
Authors: Kemper Kristel , Versloot Miranda , Cameron Katherine , Colak Selçuk , de Sousa e Melo Felipe , de Jong Joan H. , Bleackley Joanne , Vermeulen Louis , Versteeg Rogier , Koster Jan , Medema Jan Paul
Published: April 2023

PDF file, 193KB, Clinicopathological characteristics of CRC patients analyzed by chi square test.
Supplementary Figure Legend from Mutations in the Ras–Raf Axis Underlie the Prognostic Value of CD133 in Colorectal Cancer
Authors: Kemper Kristel , Versloot Miranda , Cameron Katherine , Colak Selçuk , de Sousa e Melo Felipe , de Jong Joan H. , Bleackley Joanne , Vermeulen Louis , Versteeg Rogier , Koster Jan , Medema Jan Paul
Published: April 2023

PDF file, 73KB.
Supplementary Figure 3b from Targeting ALDHbright Human Carcinoma–Initiating Cells with ALDH1A1-Specific CD8+ T Cells
Authors: Visus Carmen , Wang Yangyang , Lozano-Leon Antonio , Ferris Robert L. , Silver Susan , Szczepanski Miroslaw J. , Brand Randall E. , Ferrone Cristina R. , Whiteside Theresa L. , Ferrone Soldano , DeLeo Albert B. , Wang Xinhui
Published: April 2023

PDF file - 52KB
Supplementary Figure 2 from Targeting ALDHbright Human Carcinoma–Initiating Cells with ALDH1A1-Specific CD8+ T Cells
Authors: Visus Carmen , Wang Yangyang , Lozano-Leon Antonio , Ferris Robert L. , Silver Susan , Szczepanski Miroslaw J. , Brand Randall E. , Ferrone Cristina R. , Whiteside Theresa L. , Ferrone Soldano , DeLeo Albert B. , Wang Xinhui
Published: April 2023

PDF file - 55KB
Supplementary Figure 2 from Mutations in the Ras–Raf Axis Underlie the Prognostic Value of CD133 in Colorectal Cancer
Authors: Kemper Kristel , Versloot Miranda , Cameron Katherine , Colak Selçuk , de Sousa e Melo Felipe , de Jong Joan H. , Bleackley Joanne , Vermeulen Louis , Versteeg Rogier , Koster Jan , Medema Jan Paul
Published: April 2023

PDF file, 655KB, Correlation in expression levels between different CSC markers.
Supplementary Data from EGFR-Homing dsRNA Activates Cancer-Targeted Immune Response and Eliminates Disseminated EGFR-Overexpressing Tumors in Mice
Authors: Shir Alexei , Ogris Manfred , Roedl Wolfgang , Wagner Ernst , Levitzki Alexander
Published: April 2023

Supplementary Figures S1-S3 and Supplementary Table S1.
Supplementary Figures 1-4, Table 1 from Sorafenib Is an Inhibitor of UGT1A1 but Is Metabolized by UGT1A9: Implications of Genetic Variants on Pharmacokinetics and Hyperbilirubinemia
Authors: Peer Cody J. , Sissung Tristan M. , Kim AeRang , Jain Lokesh , Woo Sukyung , Gardner Erin R. , Kirkland C. Tyler , Troutman Sarah M. , English Bevin C. , Richardson Emily D. , Federspiel Joel , Venzon David , Dahut William , Kohn Elise , Kummar Shivaani , Yarchoan Robert , Giaccone Giuseppe , Widemann Brigitte , Figg William D.
Published: April 2023

PDF file - 698K
Supplementary Legends for Tables 1-2, Figures 1-6 from Loss of Transforming Growth Factor Beta Type II Receptor Increases Aggressive Tumor Behavior and Reduces Survival in Lung Adenocarcinoma and Squamous Cell Carcinoma
Authors: Malkoski Stephen P. , Haeger Sarah M. , Cleaver Timothy G. , Rodriguez Karen J. , Li Howard , Lu Shi-Long , Feser William J. , Barón Anna E. , Merrick Daniel , Lighthall Jessyka G. , Ijichi Hideaki , Franklin Wilbur , Wang Xiao-Jing
Published: April 2023

PDF file - 80K
Supplementary Figure 3 from Novel Chemosensitive Single-Nucleotide Polymorphism Markers to Targeted Regimens in Metastatic Colorectal Cancer
Authors: Kim Jin C. , Kim Seon Y. , Cho Dong H. , Ha Ye J. , Choi Eun Y. , Kim Chan W. , Roh Seon A. , Kim Tae W. , Ju Hyoungseok , Kim Yong S.
Published: April 2023

PDF file - 1.4MB, Cell viability measured by MTT assay in transfected CRC clones (a. DFNB31 rs2274159; b. ANXA11 rs1049550; c. LINS1 rs11247226) treated with FRC (a), FRB (b), and FXB (c), respectively. Bold font, P < 0.05. FRC, FOLFIRI + cetuximab; FRB, FOLFIRI + bevacizumab; FXB, FOLFOX + bevacizumab.
Supplementary Figure 2 from Novel Chemosensitive Single-Nucleotide Polymorphism Markers to Targeted Regimens in Metastatic Colorectal Cancer
Authors: Kim Jin C. , Kim Seon Y. , Cho Dong H. , Ha Ye J. , Choi Eun Y. , Kim Chan W. , Roh Seon A. , Kim Tae W. , Ju Hyoungseok , Kim Yong S.
Published: April 2023

PDF file - 2.6MB, Genome-wide association with in vitro chemosensitivity to targeted regimens: FRB (A), FXB (B), FRC (C), and FXC (D). Association of SNPs with the inhibition ratio was tested by linear regression analysis. P-values of < 0.001 are indicated by red dots. FRB, FOLFIRI + bevacizumab; FXB, FOLFOX + bevacizumab; FRC, FOLFIRI + cetuximab; FXC, FOLFOX + cetuximab.
Supplementary Figure 1 from Novel Chemosensitive Single-Nucleotide Polymorphism Markers to Targeted Regimens in Metastatic Colorectal Cancer
Authors: Kim Jin C. , Kim Seon Y. , Cho Dong H. , Ha Ye J. , Choi Eun Y. , Kim Chan W. , Roh Seon A. , Kim Tae W. , Ju Hyoungseok , Kim Yong S.
Published: April 2023

PDF file - 376K, Inhibition rates (IR) of tumor growth (A) and response rates at IR30 (chemosensitivity) (B). The IRs and IR30 of a single bevacizumab or cetuximab regimen were significantly less than those of the other four combination regimens (P � 0.001). IR, inhibition rate; FRB, FOLFIRI + bevacizumab; FXB, FOLFOX + bevacizumab; FRC, FOLFIRI + cetuximab; FXC, FOLFOX + cetuximab.
Supplementary Figure 2B from Survival of 1,181 Patients in a Phase I Clinic: The MD Anderson Clinical Center for Targeted Therapy Experience
Authors: Wheler Jennifer , Tsimberidou Apostolia M. , Hong David , Naing Aung , Falchook Gerald , Piha-Paul Sarina , Fu Siqing , Moulder Stacy , Stephen Bettzy , Wen Sijin , Kurzrock Razelle
Published: April 2023

PDF file, 90KB, Kaplan - Meier survival curves by dichotomized RMH score (n=1,169 patients for whom RMH score was available). Median survival is 12.3 months (95% CI: 11.2 - 13.8) for RMH score ≤1, and 5.5 months (95% CI: 4.8 - 6.6) for RMH score >1 (Log-rank p-value <0.0001).
Supplementary Figures 1-4 from Improving T-cell Therapy for Relapsed EBV-Negative Hodgkin Lymphoma by Targeting Upregulated MAGE-A4
Authors: Cruz Conrad R. , Gerdemann Ulrike , Leen Ann M. , Shafer Jessica A. , Ku Stephanie , Tzou Benjamin , Horton Terzah M. , Sheehan Andrea , Copeland Amanda , Younes Anas , Rooney Cliona M. , Heslop Helen E. , Bollard Catherine M.
Published: April 2023

PDF file - 2266KB
Supplementary Figure 1 from Significant Biological Role of Sp1 Transactivation in Multiple Myeloma
Authors: Fulciniti Mariateresa , Amin Samir , Nanjappa Puru , Rodig Scott , Prabhala Rao , Li Cheng , Minvielle Stephane , Tai Yu-tzu , Tassone Pierfrancesco , Avet-Loiseau Herve , Hideshima Teru , Anderson Kenneth C. , Munshi Nikhil C.
Published: April 2023

PDF file - 37KB
Supplementary Table 2 from Detection and Characterization of a Novel Subset of CD8+CD57+ T Cells in Metastatic Melanoma with an Incompletely Differentiated Phenotype
Authors: Wu Richard C. , Liu Shujuan , Chacon Jessica A. , Wu Sheng , Li Yufeng , Sukhumalchandra Pariya , Murray James L. , Molldrem Jeffrey J. , Hwu Patrick , Pircher Hanspeter , Lizée Gregory , Radvanyi Laszlo G.
Published: April 2023

PDF file - 82K, List of fluorochrome-conjugated flow cytometry antibodies, fluorescence labeling reagent, and suppliers used in the study.
Supplementary Materials and Methods from Detection and Characterization of a Novel Subset of CD8+CD57+ T Cells in Metastatic Melanoma with an Incompletely Differentiated Phenotype
Authors: Wu Richard C. , Liu Shujuan , Chacon Jessica A. , Wu Sheng , Li Yufeng , Sukhumalchandra Pariya , Murray James L. , Molldrem Jeffrey J. , Hwu Patrick , Pircher Hanspeter , Lizée Gregory , Radvanyi Laszlo G.
Published: April 2023

PDF file - 96K
Supplementary Figure 1 from A Novel Aldehyde Dehydrogenase-3 Activator Leads to Adult Salivary Stem Cell Enrichment In Vivo
Authors: Banh Alice , Xiao Nan , Cao Hongbin , Chen Che-Hong , Kuo Peiwen , Krakow Trevor , Bavan Brindha , Khong Brian , Yao Mike , Ha Chi , Kaplan Michael J. , Sirjani Davud , Jensen Kristin , Kong Christina S. , Mochly-Rosen Daria , Koong Albert C. , Le Quynh-Thu
Published: April 2023

PDF file - 600K
Supplementary Table 6 from High-Risk Ovarian Cancer Based on 126-Gene Expression Signature Is Uniquely Characterized by Downregulation of Antigen Presentation Pathway
Authors: Yoshihara Kosuke , Tsunoda Tatsuhiko , Shigemizu Daichi , Fujiwara Hiroyuki , Hatae Masayuki , Fujiwara Hisaya , Masuzaki Hideaki , Katabuchi Hidetaka , Kawakami Yosuke , Okamoto Aikou , Nogawa Takayoshi , Matsumura Noriomi , Udagawa Yasuhiro , Saito Tsuyoshi , Itamochi Hiroaki , Takano Masashi , Miyagi Etsuko , Sudo Tamotsu , Ushijima Kimio , Iwase Haruko , Seki Hiroyuki , Terao Yasuhisa , Enomoto Takayuki , Mikami Mikio , Akazawa Kohei , Tsuda Hitoshi , Moriya Takuya , Tajima Atsushi , Inoue Ituro , Tanaka Kenichi
Published: April 2023

PDF file - 338K
Supplementary Figure 10 from Detection and Characterization of a Novel Subset of CD8+CD57+ T Cells in Metastatic Melanoma with an Incompletely Differentiated Phenotype
Authors: Wu Richard C. , Liu Shujuan , Chacon Jessica A. , Wu Sheng , Li Yufeng , Sukhumalchandra Pariya , Murray James L. , Molldrem Jeffrey J. , Hwu Patrick , Pircher Hanspeter , Lizée Gregory , Radvanyi Laszlo G.
Published: April 2023

PDF file - 69K, Flow cytometry plots of the purity of the TIL subsets after cell sorting.
Supplementary Table 5 from A Three-Gene Expression Signature Model for Risk Stratification of Patients with Neuroblastoma
Authors: Garcia Idoia , Mayol Gemma , Ríos José , Domenech Gema , Cheung Nai-Kong V. , Oberthuer André , Fischer Matthias , Maris John M. , Brodeur Garrett M. , Hero Barbara , Rodríguez Eva , Suñol Mariona , Galvan Patricia , de Torres Carmen , Mora Jaume , Lavarino Cinzia
Published: April 2023

PDF file - 24K
Supplementary Table 1 from A Three-Gene Expression Signature Model for Risk Stratification of Patients with Neuroblastoma
Authors: Garcia Idoia , Mayol Gemma , Ríos José , Domenech Gema , Cheung Nai-Kong V. , Oberthuer André , Fischer Matthias , Maris John M. , Brodeur Garrett M. , Hero Barbara , Rodríguez Eva , Suñol Mariona , Galvan Patricia , de Torres Carmen , Mora Jaume , Lavarino Cinzia
Published: April 2023

XLS file - 61K
Supplementary Figure 5 from High-Risk Ovarian Cancer Based on 126-Gene Expression Signature Is Uniquely Characterized by Downregulation of Antigen Presentation Pathway
Authors: Yoshihara Kosuke , Tsunoda Tatsuhiko , Shigemizu Daichi , Fujiwara Hiroyuki , Hatae Masayuki , Fujiwara Hisaya , Masuzaki Hideaki , Katabuchi Hidetaka , Kawakami Yosuke , Okamoto Aikou , Nogawa Takayoshi , Matsumura Noriomi , Udagawa Yasuhiro , Saito Tsuyoshi , Itamochi Hiroaki , Takano Masashi , Miyagi Etsuko , Sudo Tamotsu , Ushijima Kimio , Iwase Haruko , Seki Hiroyuki , Terao Yasuhisa , Enomoto Takayuki , Mikami Mikio , Akazawa Kohei , Tsuda Hitoshi , Moriya Takuya , Tajima Atsushi , Inoue Ituro , Tanaka Kenichi
Published: April 2023

PDF file - 190K
Supplementary Figure Legend from Therapeutic Effect of Lenalidomide in a Novel Xenograft Mouse Model of Human Blastic NK Cell Lymphoma/Blastic Plasmacytoid Dendritic Cell Neoplasm
Authors: Agliano Alice , Martin-Padura Ines , Marighetti Paola , Gregato Giuliana , Calleri Angelica , Prior Celia , Redrado Miriam , Calvo Alfonso , Bertolini Francesco
Published: April 2023

PDF file - 62KB
Supplementary Figure 3 from Mitoxantrone Inhibits HIF-1α Expression in a Topoisomerase II–Independent Pathway
Authors: Toh Yng-Miin , Li Tsai-Kun
Published: April 2023

PDF file - 172K
Supplementary Table 8 from Integrative Genomics Identified RFC3 As an Amplified Candidate Oncogene in Esophageal Adenocarcinoma
Authors: Lockwood William W. , Thu Kelsie L. , Lin Lin , Pikor Larissa A. , Chari Raj , Lam Wan L. , Beer David G.
Published: April 2023

PDF file - 219K
Supplementary Materials and Methods from Proximal Fluid Proteome Profiling of Mouse Colon Tumors Reveals Biomarkers for Early Diagnosis of Human Colorectal Cancer
Authors: Fijneman Remond J.A. , de Wit Meike , Pourghiasian Maral , Piersma Sander R. , Pham Thang V. , Warmoes Marc O. , Lavaei Mehrdad , Piso Chloe , Smit Fiona , Delis-van Diemen Pien M. , van Turenhout Sietze T. , Terhaar sive Droste Jochim S. , Mulder Chris J.J. , Blankenstein Marinus A. , Robanus-Maandag Els C. , Smits Ron , Fodde Riccardo , van Hinsbergh Victor W.M. , Meijer Gerrit A. , Jimenez Connie R.
Published: April 2023

PDF file - 72K
Supplementary Table 7 from Integrative Genomics Identified RFC3 As an Amplified Candidate Oncogene in Esophageal Adenocarcinoma
Authors: Lockwood William W. , Thu Kelsie L. , Lin Lin , Pikor Larissa A. , Chari Raj , Lam Wan L. , Beer David G.
Published: April 2023

XLS file - 42K
Supplementary Table 5 from Integrative Genomics Identified RFC3 As an Amplified Candidate Oncogene in Esophageal Adenocarcinoma
Authors: Lockwood William W. , Thu Kelsie L. , Lin Lin , Pikor Larissa A. , Chari Raj , Lam Wan L. , Beer David G.
Published: April 2023

PDF file - 194K
Supplementary Figure 3 from Protein Kinase CK2 Protects Multiple Myeloma Cells from ER Stress–Induced Apoptosis and from the Cytotoxic Effect of HSP90 Inhibition through Regulation of the Unfolded Protein Response
Authors: Manni Sabrina , Brancalion Alessandra , Tubi Laura Quotti , Colpo Anna , Pavan Laura , Cabrelle Anna , Ave Elisa , Zaffino Fortunato , Di Maira Giovanni , Ruzzene Maria , Adami Fausto , Zambello Renato , Pitari Maria Rita , Tassone Pierfrancesco , Pinna Lorenzo A. , Gurrieri Carmela , Semenzato Gianpietro , Piazza Francesco
Published: April 2023

PDF file - 44K
Supplementary Figure 3 from The Phosphatase Inhibitor Menadione (Vitamin K3) Protects Cells from EGFR Inhibition by Erlotinib and Cetuximab
Authors: Perez-Soler Roman , Zou Yiyu , Li Tianhong , Ling Yi He
Published: April 2023

PDF file - 57KB, Effect of exogenous EGF on EGFR tyrosine kinase inhibition by erlotinib or cetuximab in A431 cells.
Supplementary Table 1 from Immune Suppression in Premalignant Respiratory Papillomas: Enriched Functional CD4+Foxp3+ Regulatory T Cells and PD-1/PD-L1/L2 Expression
Authors: Hatam Lynda J. , DeVoti James A. , Rosenthal David W. , Lam Fung , Abramson Allan L. , Steinberg Bettie M. , Bonagura Vincent R.
Published: April 2023

PDF file - 41K
Supplementary Figure 5 from Tumor-Derived Autophagosome Vaccine: Mechanism of Cross-Presentation and Therapeutic Efficacy
Authors: Li Yuhuan , Wang Li-Xin , Pang Puiyi , Cui Zhihua , Aung Sandra , Haley Daniel , Fox Bernard A. , Urba Walter J. , Hu Hong-Ming
Published: April 2023

PDF file - 689K
Supplementary Figure 3 from Tumor-Derived Autophagosome Vaccine: Mechanism of Cross-Presentation and Therapeutic Efficacy
Authors: Li Yuhuan , Wang Li-Xin , Pang Puiyi , Cui Zhihua , Aung Sandra , Haley Daniel , Fox Bernard A. , Urba Walter J. , Hu Hong-Ming
Published: April 2023

PDF file - 613K
Supplementary Figure 2 from Tumor-Derived Autophagosome Vaccine: Mechanism of Cross-Presentation and Therapeutic Efficacy
Authors: Li Yuhuan , Wang Li-Xin , Pang Puiyi , Cui Zhihua , Aung Sandra , Haley Daniel , Fox Bernard A. , Urba Walter J. , Hu Hong-Ming
Published: April 2023

PDF file - 650K
Supplementary Figure 2 from Preclinical Testing of PI3K/AKT/mTOR Signaling Inhibitors in a Mouse Model of Ovarian Endometrioid Adenocarcinoma
Authors: Wu Rong , Hu Tom C. , Rehemtulla Alnawaz , Fearon Eric R. , Cho Kathleen R.
Published: April 2023

PDF file - 111K, Characterization of PI3K/Akt/mTOR and Erk signaling pathway regulation in human ovarian cancer cells after treatment with mTOR inhibitor rapamycin. Immunoblots showing dose-dependent effect of rapamycin (0.01 - 100nM) on phosphorylation of Akt, Erk, S6K1, S6, 4E-BP1, and GSK3� after exposure to rapamycin for 2 hours in A) TOV112D and B) A2780 cells transduced with mutant �-catenin (A2780-S33Y) or vector alone (A2780-Neo). Effects of rapamycin on the transcriptionally active (dephosphorylated on Ser37 or Thr41) form of �-catenin is also shown.
Supplementary Figure Legends 1-3 from Analyzing the Pivotal Trial That Compared Sunitinib and IFN-α in Renal Cell Carcinoma, Using a Method That Assesses Tumor Regression and Growth
Authors: Stein Wilfred D. , Wilkerson Julia , Kim Sindy T. , Huang Xin , Motzer Robert J. , Fojo Antonio Tito , Bates Susan E.
Published: April 2023

PDF file - 69K
Supplementary Figure 2 from Analyzing the Pivotal Trial That Compared Sunitinib and IFN-α in Renal Cell Carcinoma, Using a Method That Assesses Tumor Regression and Growth
Authors: Stein Wilfred D. , Wilkerson Julia , Kim Sindy T. , Huang Xin , Motzer Robert J. , Fojo Antonio Tito , Bates Susan E.
Published: April 2023

PDF file - 60K
Supplementary Figure 1, Table 1 from Genetic Variation Predicting Cisplatin Cytotoxicity Associated with Overall Survival in Lung Cancer Patients Receiving Platinum-Based Chemotherapy
Authors: Tan Xiang-Lin , Moyer Ann M. , Fridley Brooke L. , Schaid Daniel J. , Niu Nifang , Batzler Anthony J. , Jenkins Gregory D. , Abo Ryan P. , Li Liang , Cunningham Julie M. , Sun Zhifu , Yang Ping , Wang Liewei
Published: April 2023

PDF file - 165K
Supplementary Table 2 from iASPP and Chemoresistance in Ovarian Cancers: Effects on Paclitaxel-Mediated Mitotic Catastrophe
Authors: Jiang LiLi , Siu Michelle K.Y. , Wong Oscar G.W. , Tam Kai-Fai , Lu Xin , Lam Eric W-F. , Ngan Hextan Y.S. , Le Xiao-Feng , Wong Esther S.Y. , Monteiro Lara J. , Chan Hoi-Yan , Cheung Annie N.Y.
Published: April 2023

PDF file - 64K
Supplementary Figure 4 from VTX-2337 Is a Novel TLR8 Agonist That Activates NK Cells and Augments ADCC
Authors: Lu Hailing , Dietsch Gregory N. , Matthews Maura-Ann H. , Yang Yi , Ghanekar Smita , Inokuma Margaret , Suni Maria , Maino Vernon C. , Henderson Katherine E. , Howbert James Jeffry , Disis Mary L. , Hershberg Robert M.
Published: April 2023

PDF file - 92K
Supplementary Table 6 from Comprehensive Genome Methylation Analysis in Bladder Cancer: Identification and Validation of Novel Methylated Genes and Application of These as Urinary Tumor Markers
Authors: Reinert Thomas , Modin Charlotte , Castano Francisco M. , Lamy Philippe , Wojdacz Tomasz K. , Hansen Lise Lotte , Wiuf Carsten , Borre Michael , Dyrskjøt Lars , Ørntoft Torben F.
Published: April 2023

PDF file - 56K
Supplementary Table 1 from Impact of the Integrin Signaling Adaptor Protein NEDD9 on Prognosis and Metastatic Behavior of Human Lung Cancer
Authors: Kondo Shunsuke , Iwata Satoshi , Yamada Taketo , Inoue Yusuke , Ichihara Hiromi , Kichikawa Yoshiko , Katayose Tomoki , Souta-Kuribara Akiko , Yamazaki Hiroto , Hosono Osamu , Kawasaki Hiroshi , Tanaka Hirotoshi , Hayashi Yuichiro , Sakamoto Michiie , Kamiya Kazunori , Dang Nam H. , Morimoto Chikao
Published: April 2023

XLS file, 27K, Clinical characteristics of evaluated NSCLC patients and classification according to NEDD9 expression in the primary tumors
Supplementary Table 2 from Comprehensive Genome Methylation Analysis in Bladder Cancer: Identification and Validation of Novel Methylated Genes and Application of These as Urinary Tumor Markers
Authors: Reinert Thomas , Modin Charlotte , Castano Francisco M. , Lamy Philippe , Wojdacz Tomasz K. , Hansen Lise Lotte , Wiuf Carsten , Borre Michael , Dyrskjøt Lars , Ørntoft Torben F.
Published: April 2023

PDF file - 90K
Supplementary Table 12 from Comprehensive Genome Methylation Analysis in Bladder Cancer: Identification and Validation of Novel Methylated Genes and Application of These as Urinary Tumor Markers
Authors: Reinert Thomas , Modin Charlotte , Castano Francisco M. , Lamy Philippe , Wojdacz Tomasz K. , Hansen Lise Lotte , Wiuf Carsten , Borre Michael , Dyrskjøt Lars , Ørntoft Torben F.
Published: April 2023

PDF file - 95K
Supplementary Figure Legend from Toll-like Receptor 9 Agonist IMO Cooperates with Cetuximab in K-Ras Mutant Colorectal and Pancreatic Cancers
Authors: Rosa Roberta , Melisi Davide , Damiano Vincenzo , Bianco Roberto , Garofalo Sonia , Gelardi Teresa , Agrawal Sudhir , Di Nicolantonio Federica , Scarpa Aldo , Bardelli Alberto , Tortora Giampaolo
Published: April 2023

PDF file - 70KB
Supplementary Table 10 from Comprehensive Genome Methylation Analysis in Bladder Cancer: Identification and Validation of Novel Methylated Genes and Application of These as Urinary Tumor Markers
Authors: Reinert Thomas , Modin Charlotte , Castano Francisco M. , Lamy Philippe , Wojdacz Tomasz K. , Hansen Lise Lotte , Wiuf Carsten , Borre Michael , Dyrskjøt Lars , Ørntoft Torben F.
Published: April 2023

XLS file - 152K
Supplementary Figure 2 from Toll-like Receptor 9 Agonist IMO Cooperates with Cetuximab in K-Ras Mutant Colorectal and Pancreatic Cancers
Authors: Rosa Roberta , Melisi Davide , Damiano Vincenzo , Bianco Roberto , Garofalo Sonia , Gelardi Teresa , Agrawal Sudhir , Di Nicolantonio Federica , Scarpa Aldo , Bardelli Alberto , Tortora Giampaolo
Published: April 2023

PDF file - 1498KB
Supplementary Figure 1 from Toll-like Receptor 9 Agonist IMO Cooperates with Cetuximab in K-Ras Mutant Colorectal and Pancreatic Cancers
Authors: Rosa Roberta , Melisi Davide , Damiano Vincenzo , Bianco Roberto , Garofalo Sonia , Gelardi Teresa , Agrawal Sudhir , Di Nicolantonio Federica , Scarpa Aldo , Bardelli Alberto , Tortora Giampaolo
Published: April 2023

PDF file - 993KB
Supplementary Figure 3 from Comprehensive Genome Methylation Analysis in Bladder Cancer: Identification and Validation of Novel Methylated Genes and Application of These as Urinary Tumor Markers
Authors: Reinert Thomas , Modin Charlotte , Castano Francisco M. , Lamy Philippe , Wojdacz Tomasz K. , Hansen Lise Lotte , Wiuf Carsten , Borre Michael , Dyrskjøt Lars , Ørntoft Torben F.
Published: April 2023

PDF file - 388K
Supplementary Table 1 from The Reconstruction of Transcriptional Networks Reveals Critical Genes with Implications for Clinical Outcome of Multiple Myeloma
Authors: Agnelli Luca , Forcato Mattia , Ferrari Francesco , Tuana Giacomo , Todoerti Katia , Walker Brian A. , Morgan Gareth J. , Lombardi Luigia , Bicciato Silvio , Neri Antonino
Published: April 2023

PDF file - 176K
Supplementary Table 1 from A Phase I Dose–Escalation Study of Regorafenib (BAY 73–4506), an Inhibitor of Oncogenic, Angiogenic, and Stromal Kinases, in Patients with Advanced Solid Tumors
Authors: Mross Klaus , Frost Annette , Steinbild Simone , Hedbom Susanne , Büchert Martin , Fasol Ulrike , Unger Clemens , Krätzschmar Jörn , Heinig Roland , Boix Oliver , Christensen Olaf
Published: April 2023

PDF file, 52KB, Adverse events that led to permanent treatment discontinuation.
CCR Translation for This Article from The Reconstruction of Transcriptional Networks Reveals Critical Genes with Implications for Clinical Outcome of Multiple Myeloma
Authors: Agnelli Luca , Forcato Mattia , Ferrari Francesco , Tuana Giacomo , Todoerti Katia , Walker Brian A. , Morgan Gareth J. , Lombardi Luigia , Bicciato Silvio , Neri Antonino
Published: April 2023

CCR Translation for This Article from The Reconstruction of Transcriptional Networks Reveals Critical Genes with Implications for Clinical Outcome of Multiple Myeloma
Supplementary Figure 2 from Neutrophil Degranulation and Immunosuppression in Patients with GBM: Restoration of Cellular Immune Function by Targeting Arginase I
Authors: Sippel Trisha R. , White Jason , Nag Kamalika , Tsvankin Vadim , Klaassen Marci , Kleinschmidt-DeMasters B.K. , Waziri Allen
Published: April 2023

PDF file - 44K
Supplementary Figure 1 from Neutrophil Degranulation and Immunosuppression in Patients with GBM: Restoration of Cellular Immune Function by Targeting Arginase I
Authors: Sippel Trisha R. , White Jason , Nag Kamalika , Tsvankin Vadim , Klaassen Marci , Kleinschmidt-DeMasters B.K. , Waziri Allen
Published: April 2023

PDF file - 45K
Supplementary Figure Legends 1-3 from Phase I/II Trial of Carboplatin and Paclitaxel Chemotherapy in Combination with Intravenous Oncolytic Reovirus in Patients with Advanced Malignancies
Authors: Karapanagiotou Eleni M. , Roulstone Victoria , Twigger Katie , Ball Mercel , Tanay MaryAnne , Nutting Chris , Newbold Kate , Gore Martin E. , Larkin James , Syrigos Konstantinos N. , Coffey Matt , Thompson Brad , Mettinger Karl , Vile Richard G. , Pandha Hardev S. , Hall Geoff D. , Melcher Alan A. , Chester John , Harrington Kevin J.
Published: April 2023

PDF file - 48K
Supplementary Figure Legends 1-10 from Ran Is a Potential Therapeutic Target for Cancer Cells with Molecular Changes Associated with Activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK Pathways
Authors: Yuen Hiu-Fung , Chan Ka-Kui , Grills Claire , Murray James T. , Platt-Higgins Angela , Eldin Osama Sharaf , O'Byrne Ken , Janne Pasi , Fennell Dean A. , Johnston Patrick G. , Rudland Philip S. , El-Tanani Mohamed
Published: April 2023

PDF file - 93K
Supplementary Figure 9 from Ran Is a Potential Therapeutic Target for Cancer Cells with Molecular Changes Associated with Activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK Pathways
Authors: Yuen Hiu-Fung , Chan Ka-Kui , Grills Claire , Murray James T. , Platt-Higgins Angela , Eldin Osama Sharaf , O'Byrne Ken , Janne Pasi , Fennell Dean A. , Johnston Patrick G. , Rudland Philip S. , El-Tanani Mohamed
Published: April 2023

PDF file - 13.3MB, High level of Ran is correlated with shorter survival time of lung cancer patients.(A) Representative images for IHC staining in lung cancer specimens. Lung cancer specimens stained with different patterns for Ran. Upper panel, 40x magnification; Lower panel, 200x magnification of the same cases. (B) Kaplan-Meier plot of the survival of lung cancer patients using combined nuclear and cytoplasmic expression of Ran; High level, high level expression of both nuclear and cytoplasmc Ran; Intermediate level, high level expression of either nuclear or cytoplasmic Ran; Low level, low level expression of both nuclear and cytoplasmic Ran. Cumulative proportion of lung cancer patients surviving with time is plotted for high, intermediate and low Ran groups. (C) Kaplan-Meier plot of survival of lung cancer patients from seven microarray datasets available in GEO database. Cumulative proportion of lung cancer patients surviving with time is plotted for high (top 25% of patients expressing a high level of Ran) and low (bottom 25% of patients expressing a low level of Ran) Ran groups.
Supplementary Figure 8 from Ran Is a Potential Therapeutic Target for Cancer Cells with Molecular Changes Associated with Activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK Pathways
Authors: Yuen Hiu-Fung , Chan Ka-Kui , Grills Claire , Murray James T. , Platt-Higgins Angela , Eldin Osama Sharaf , O'Byrne Ken , Janne Pasi , Fennell Dean A. , Johnston Patrick G. , Rudland Philip S. , El-Tanani Mohamed
Published: April 2023

PDF file - 3.5, MTT assay showing that cancer cells with K-Ras activation mutation (HCT116/Hkh-2 and DLD1/DKO3 isogenic pairs) and c-Met (HCC827 parental/GR5 pair) are more susceptible to Ran silencing-induced apoptosis. (A) In HCT116/Hkh-2 colon cancer isogenic pair, HCT116 cells, which contain K-Ras activation mutation, are more susceptible to apoptosis induction by the 5 shRNAs targeting Ran, compared to the K-Ras wild-type counterpart, Hkh-2. (B) In DLD1/DKO3 colon cancer isogenic pair, DLD1 cells, which contain K-Ras activation mutation, are more susceptible to apoptosis induction by the 2 shRNAs targeting Ran, compared to the K-Ras wild-type counterpart, DKO3. (C) In HCC827 parental/GR5 lung cancer pair, the GR5 cells, which contain c-Met amplification, are more susceptible to apoptosis induction by the 2 shRNAs targeting Ran, compared to the wild-type HCC827 cells. Results are plotted as histogram showing the mean � SD from three independent experiments. Key; *, ** and *** represent p < 0.05, <0.01 and <0.001, respectively. Representative blots from three independent experiments are shown.
Supplementary Figure 7 from Ran Is a Potential Therapeutic Target for Cancer Cells with Molecular Changes Associated with Activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK Pathways
Authors: Yuen Hiu-Fung , Chan Ka-Kui , Grills Claire , Murray James T. , Platt-Higgins Angela , Eldin Osama Sharaf , O'Byrne Ken , Janne Pasi , Fennell Dean A. , Johnston Patrick G. , Rudland Philip S. , El-Tanani Mohamed
Published: April 2023

PDF file - 3.6K, Cancer cells with K-Ras activation mutation (HCT116/Hkh-2 isogenic pair) are more susceptible to Ran silencing-induced apoptosis.
Related Article from Is It Downhill from Here? Eliminating Leukemic Stem Cells and Curing Chronic Myeloid Leukemia
Authors: Smith Catherine C. , Shah Neil P.
Published: April 2023

Related Article from Is It Downhill from Here? Eliminating Leukemic Stem Cells and Curing Chronic Myeloid Leukemia
Supplementary Figure 4 from Ran Is a Potential Therapeutic Target for Cancer Cells with Molecular Changes Associated with Activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK Pathways
Authors: Yuen Hiu-Fung , Chan Ka-Kui , Grills Claire , Murray James T. , Platt-Higgins Angela , Eldin Osama Sharaf , O'Byrne Ken , Janne Pasi , Fennell Dean A. , Johnston Patrick G. , Rudland Philip S. , El-Tanani Mohamed
Published: April 2023

PDF file - 4.8, Effect of chemical inhibitors on the activity of signaling pathways in MDA MB231 and A549 cells expressing various levels of Ran. Western blots of phospho- and total Akt, ERK and S6K proteins in MDA MB231 and A549 cells expressing various levels of Ran grown in different growth conditions. Representative blots from two independent experiments are shown.
Supplementary Figure Legend from Comparison of Continuous versus Categorical Tumor Measurement–Based Metrics to Predict Overall Survival in Cancer Treatment Trials
Authors: An Ming-Wen , Mandrekar Sumithra J. , Branda Megan E. , Hillman Shauna L. , Adjei Alex A. , Pitot Henry C. , Goldberg Richard M. , Sargent Daniel J.
Published: April 2023

PDF file - 45KB
Supplementary Table 1 from Outcomes of Phase II Clinical Trials with Single-Agent Therapies in Advanced/Metastatic Non–Small Cell Lung Cancer Published between 2000 and 2009
Authors: Janku Filip , Berry Donald A. , Gong Jing , Parsons Henrique A. , Stewart David J. , Kurzrock Razelle
Published: April 2023

PDF file - 73K, Drugs and therapeutic targets in the analyzed studies
Supplementary Appendix 1 from Outcomes of Phase II Clinical Trials with Single-Agent Therapies in Advanced/Metastatic Non–Small Cell Lung Cancer Published between 2000 and 2009
Authors: Janku Filip , Berry Donald A. , Gong Jing , Parsons Henrique A. , Stewart David J. , Kurzrock Razelle
Published: April 2023

PDF file - 43K, All analyzed studies
Supplementary Methods, Figures 1 - 7, Tables 1 - 10 from Evaluation of Midkine as a Diagnostic Serum Biomarker in Hepatocellular Carcinoma
Authors: Zhu Wen-Wei , Guo Jia-Jian , Guo Lei , Jia Hu-Liang , Zhu Ming , Zhang Ju-Bo , Loffredo Christopher A. , Forgues Marshonna , Huang Hua , Xing Xu-Jian , Ren Ning , Dong Qiong-Zhu , Zhou Hai-Jun , Ren Zheng-Gang , Zhao Nai-Qing , Wang Xin Wei , Tang Zhao-You , Qin Lun-Xiu , Ye Qing-Hai
Published: April 2023

PDF file - 589K, Supplementary Fig. S1 Elevated MDK levels in the culture medium of HCC cell lines compared with normal liver cell lines. Supplementary Fig. S2 The prognostic values of AFP and MDK levels for HCC patients. Supplementary Fig. S3.Expression of serum MDK in another independent cohort (cohort B) from Egypt. Supplementary Fig. S4. Logistic Regression Model to combine information of MDK and AFP for prediction of HCC in the learning cohort A (n=252): Comparison of AUROC for diagnosis HCC through logist regression model I, serum MDK and AFP. Supplementary Fig. S5. Positive predictive value (PPV) and negative predictive value (NPV) for identifying HCC patients through serum MDK according to different prevalence. Supplementary Fig. S6. Correlation between serum AFP and MDK levels in HCC patients (n=252). Supplementary Fig. S7. Serum MDK is elevated in different HCC subsets, No significant difference in serum MDK levels was found between the learning cohort A and the external validation cohort of HCC patients(P=0.398), or between the early stage HCC patients in learning and validation cohort (P=0.295). Table S1. Relationship between MDK expression and clinicopathological features of HCC patients. Table S2. Clinical and biochemical characteristics of liver cirrhosis (LC) patients in cohort A. Table S3. Baseline characteristics of the hospital controls with different etiologies from learning Cohort A. Table S4. Clinical characteristics of HCC patients according to different cohorts in this study. Table S5. MDK protein levels in cancer-free cirrhotic liver and HCC tissues. Table S6. Comparison of AFP and MDK with clinicopathological parameters in learning cohort A. Table S7．Univariate Cox-regression Analyses of Factors Associated With OS and TTR. Table S8. Sensitivities and specificities of AFP and MDK according to various cutoff values. Table S9. Cross-validation of the diagnostic ability of serum MDK. Table S10. Comparison of MDK with clinicopathological parameters in validation cohort C.
Supplementary Materials from A Phase I Pharmacokinetic and Pharmacodynamic Study of CHR-3996, an Oral Class I Selective Histone Deacetylase Inhibitor in Refractory Solid Tumors
Authors: Banerji Udai , van Doorn Leni , Papadatos-Pastos Dionysis , Kristeleit Rebecca , Debnam Phillip , Tall Matthew , Stewart Adam , Raynaud Florence , Garrett Michelle Dawn , Toal Martin , Hooftman Leon , De Bono Johann Sebastian , Verweij Jaap , Eskens Ferry ALM
Published: April 2023

PDF file - 82K, Inclusion Criteria and Analysis
Supplementary Table 1 from Vemurafenib Synergizes with Nutlin-3 to Deplete Survivin and Suppresses Melanoma Viability and Tumor Growth
Authors: Ji Zhenyu , Kumar Raj , Taylor Michael , Rajadurai Anpuchchelvi , Marzuka-Alcalá Alexander , Chen Y. Erin , Njauw Ching-Ni Jenny , Flaherty Keith , Jönsson Göran , Tsao Hensin
Published: April 2023

PDF file, 89K, These are molecules that respond to vemurafenib.
Supplementary Figure S4 from Radiotherapy of Human Sarcoma Promotes an Intratumoral Immune Effector Signature
Authors: Sharma Anu , Bode Beata , Studer Gabriela , Moch Holger , Okoniewski Michal , Knuth Alexander , von Boehmer Lotta , van den Broek Maries
Published: April 2023

Supplementary Figure S4 - PDF file 140K, Summary of radiotherapy-induced changes of immune response-related gene expression in human sarcoma: Retrospective analysis of 37 paired samples before/after radiotherapy by qRT-PCR for (A) immune effector molecules (B) immune suppressor molecules (C) cytokines (D) CT-antigens and (E) transcription factors. The horizontal bars on the bar graphs represent the median. Statistical analysis was performed for each transcript between the cohort before (open bars) and after (stippled bars) radiotherapy using the two-tailed bivariate analysis (Graphpad-Prism) on the delta Ct values after normalization to beta-actin. The p-values of statistically different groups are displayed in the graph. The data for individual patients are shown in Fig. 1
Data Supplement from Comprehensive Biomarker Analysis and Final Efficacy Results of Sorafenib in the BATTLE Trial
Authors: Blumenschein George R. , Saintigny Pierre , Liu Suyu , Kim Edward S. , Tsao Anne S. , Herbst Roy S. , Alden Christine , Lee J. Jack , Tang Ximing , Stewart David J. , Kies Merrill S. , Fossella Frank V. , Tran Hai T. , Mao L. , Hicks Marshall E. , Erasmus Jeremy , Gupta Sanjay , Girard Luc , Peyton Michael , Diao Lixia , Wang Jing , Davis Suzanne E. , Minna John D. , Wistuba Ignacio , Hong Waun K. , Heymach John V. , Lippman Scott M.
Published: April 2023

Supplementary Table 1. Non-small cell lung cancer cell lines used to develop the sorafenib sensitivity signature.
Supplementary Table 1 from Bridging the Gap between Preclinical and Clinical Studies Using Pharmacokinetic–Pharmacodynamic Modeling: An Analysis of GDC-0973, a MEK Inhibitor
Authors: Wong Harvey , Vernillet Laurent , Peterson Amy , Ware Joseph A. , Lee Lillian , Martini Jean-Francois , Yu Peiwen , Li Congfen , Rosario Geoffrey Del , Choo Edna F. , Hoeflich Klaus P. , Shi Yongchang , Aftab Blake T. , Aoyama Ron , Lam Sanh Tan , Belvin Marcia , Prescott John
Published: April 2023

PDF file, 72KB, Summary of pharmacokinetic parameters estimated from fitting PK model from WM-266-4 xenograft studies (Figure 1A) to GDC-0973 concentration-time data from humans.
Supplementary Figure Legend from Bridging the Gap between Preclinical and Clinical Studies Using Pharmacokinetic–Pharmacodynamic Modeling: An Analysis of GDC-0973, a MEK Inhibitor
Authors: Wong Harvey , Vernillet Laurent , Peterson Amy , Ware Joseph A. , Lee Lillian , Martini Jean-Francois , Yu Peiwen , Li Congfen , Rosario Geoffrey Del , Choo Edna F. , Hoeflich Klaus P. , Shi Yongchang , Aftab Blake T. , Aoyama Ron , Lam Sanh Tan , Belvin Marcia , Prescott John
Published: April 2023

PDF file, 62KB.
Supplementary Table 1 from Nanoparticles Engineered with Rituximab and Loaded with Nutlin-3 Show Promising Therapeutic Activity in B-Leukemic Xenografts
Authors: Voltan Rebecca , Secchiero Paola , Ruozi Barbara , Forni Flavio , Agostinis Chiara , Caruso Lorenzo , Vandelli Maria Angela , Zauli Giorgio
Published: April 2023

PDF file - 83K, Supplementary Table 1. Physicochemical properties and technological characterization of the NP-Nut, NP-Rt and NP-Rt-Nut preparations.
Supplementary Figure 6 from Acquired Resistance to Anti-VEGF Therapy in Glioblastoma Is Associated with a Mesenchymal Transition
Authors: Piao Yuji , Liang Ji , Holmes Lindsay , Henry Verlene , Sulman Erik , de Groot John F.
Published: April 2023

PDF file, 809K, TGF-beta increases following the acquisition of bevacizumab resistance.
Supplementary Figure Legend from Aberrant BAF57 Signaling Facilitates Prometastatic Phenotypes
Authors: Balasubramaniam Sucharitha , Comstock Clay E.S. , Ertel Adam , Jeong Kwang Won , Stallcup Michael R. , Addya Sankar , McCue Peter A. , Ostrander William F. , Augello Michael A. , Knudsen Karen E.
Published: April 2023

PDF file - 130K
Supplementary Figure 5 from Aberrant BAF57 Signaling Facilitates Prometastatic Phenotypes
Authors: Balasubramaniam Sucharitha , Comstock Clay E.S. , Ertel Adam , Jeong Kwang Won , Stallcup Michael R. , Addya Sankar , McCue Peter A. , Ostrander William F. , Augello Michael A. , Knudsen Karen E.
Published: April 2023

PDF file - 554K, Metastatic loci from individual patients display differences in BAF57 elevation.
Supplementary Figure 1 from Acquired Resistance to Anti-VEGF Therapy in Glioblastoma Is Associated with a Mesenchymal Transition
Authors: Piao Yuji , Liang Ji , Holmes Lindsay , Henry Verlene , Sulman Erik , de Groot John F.
Published: April 2023

PDF file, 485K, HIF-1alpha is overexpressed following bevacizumab treatment
Supplementary Figure 1 from Aberrant BAF57 Signaling Facilitates Prometastatic Phenotypes
Authors: Balasubramaniam Sucharitha , Comstock Clay E.S. , Ertel Adam , Jeong Kwang Won , Stallcup Michael R. , Addya Sankar , McCue Peter A. , Ostrander William F. , Augello Michael A. , Knudsen Karen E.
Published: April 2023

PDF file - 464K, Mimicking tumor-derived BAF57 elevation in vitro.
Supplementary Tables 1 - 4 from Worth Adapting? Revisiting the Usefulness of Outcome-Adaptive Randomization
Authors: Lee J. Jack , Chen Nan , Yin Guosheng
Published: April 2023

PDF file, 72K, Supplementary Tables 1-4: S1-Rejection rate, and percent on experimental arm without early stopping.S2-Rejection rate, efficacy stopping rate, futility stopping rate, and percentage on experimental arm with both futility and efficacy early stopping. S3-Rejection rate, efficacy stopping rate, futility stopping rate, and percentage on experimental arm for the three-arm designs with both futility and efficacy early stopping. S4-Performance of equal and adaptive randomization designs for survival analysis.
Supplementary Figure 2 from Stemness of B-cell Progenitors in Multiple Myeloma Bone Marrow
Authors: Boucher Kelly , Parquet Nancy , Widen Raymond , Shain Kenneth , Baz Rachid , Alsina Melissa , Koomen John , Anasetti Claudio , Dalton William , Perez Lia E.
Published: April 2023

PDF file - 31K, DNA sequence analysis of sorted marrow sub-populations
Supplementary Figure Legends 1-2, Table Legends 1-3 from The Prognostic Significance of Vasohibin-1 Expression in Patients with Upper Urinary Tract Urothelial Carcinoma
Authors: Miyazaki Yasumasa , Kosaka Takeo , Mikami Shuji , Kikuchi Eiji , Tanaka Nobuyuki , Maeda Takahiro , Ishida Masaru , Miyajima Akira , Nakagawa Ken , Okada Yasunori , Sato Yasufumi , Oya Mototsugu
Published: April 2023

PDF file - 38K
Supplementary Figure 4 from CCT244747 Is a Novel Potent and Selective CHK1 Inhibitor with Oral Efficacy Alone and in Combination with Genotoxic Anticancer Drugs
Authors: Walton Mike I. , Eve Paul D. , Hayes Angela , Valenti Melanie R. , De Haven Brandon Alexis K. , Box Gary , Hallsworth Albert , Smith Elizabeth L. , Boxall Kathy J. , Lainchbury Michael , Matthews Thomas P. , Jamin Yann , Robinson Simon P. , Aherne G. Wynne , Reader John C. , Chesler Louis , Raynaud Florence I. , Eccles Suzanne A. , Collins Ian , Garrett Michelle D.
Published: April 2023

PDF file, 67K, Supplementary Figure 4. Effects of scheduling and exposure times on the ability of two different CHK1 inhibitors to potentiate gemcitabine cytotoxicity in SW620 cells in vitro. A, Effect of different contact times on the capacity of SAR-020106 to enhance gemcitabine cytotoxicity in SW620 cells. Gemcitabine was continuously present (96h) at an IC50 concentration and SAR- 020106 was added at the start of treatment over a range of concentrations for the intervals shown (i.e. 0-T1, 0-T2, 0-T3, etc). Growth delay and potentiation were measured using an SRB assay as described in Materials and Methods. Potentiation Index (PI) was expressed as a percentage of the maximum PI. Values are mean�SE, for n=3-5 independent experiments. B, Treatment of synchronized SW620 cells with gemcitabine and SAR-020106. Cells were synchronized with nocodazole (100ng/ml x 16h). Eight hours following release (at G1/S boundary) cells were treated with a fixed concentration of gemcitabine (GI50) for 96h combined with different concentrations of SAR-020106 for 0-96, 0-48 or 0-24h. Values are mean�SE for 3 independent determinations. C, Effects of contact time on the potentiation of gemcitabine cytotoxicity in synchronized compared to asynchronous SW620 cells. See B and Materials and Methods for further details. Values are mean�SE, n=3-5. D, Effects of different contact times and treatment schedules on the ability of CCT244747 to enhance gemcitabine cytotoxicity in SW620 cells. Values are mean�SE, for 3-7 independent experiments.
Supplementary Figure 2 from The Prognostic Significance of Vasohibin-1 Expression in Patients with Upper Urinary Tract Urothelial Carcinoma
Authors: Miyazaki Yasumasa , Kosaka Takeo , Mikami Shuji , Kikuchi Eiji , Tanaka Nobuyuki , Maeda Takahiro , Ishida Masaru , Miyajima Akira , Nakagawa Ken , Okada Yasunori , Sato Yasufumi , Oya Mototsugu
Published: April 2023

PDF file - 2.9MB, Supplementary Figure 2A. Immunostaining for CD34 in the case of pTa, low grade, and LVI negative UTUC with low VASH1 density: CD34 staining was observed in endothelial cells of microvascular vessels in the tumor lesion. Supplementary Figure 2B. Immunostaining for VASH1: the same case with 2A. VASH1 staining of vascular endothelial cells was negative or negligible. We observed low VASH1 density. Supplementary Figure 2C. Negative control slide: the same case with 2A-2B. The appropriate negative control slide was prepared. Supplementary Figure 2D. Immunostaining for CD34 in the case of pTa, low grade, and LVI negative UTUC with high VASH1 density: CD34 staining was observed in endothelial cells of microvascular vessels in the tumor lesion. Supplementary Figure 2E. Immunostaining for VASH1: the same case with 2D. VASH1 staining of vascular endothelial cells was strong. We observed high VASH1 density. Supplementary Figure 2F. Negative control slide: the same case with 2D-2E. The appropriate negative control slide was prepared. Supplementary Figure 2G. Immunostaining for CD34 in the case of pT3b, high grade, and LVI positive UTUC with low VASH1 density: CD34 staining was observed in endothelial cells of microvascular vessels in the tumor lesion. Supplementary Figure 2H. Immunostaining for VASH1: the same case with 2G. VASH1 staining of vascular endothelial cells was negative or negligible. We observed low VASH1 density. Supplementary Figure 2I. Negative control slide: the same case with 2G-2H. The appropriate negative control slide was prepared. Supplementary Figure 2J. Immunostaining for CD34 in the case of pT3b, high grade, and LVI positive UTUC with high VASH1 density: CD34 staining was observed in endothelial cells of microvascular vessels in the tumor lesion. Supplementary Figure 2K. Immunostaining for VASH1: the same case with 2J. VASH1 staining of vascular endothelial cells was strong. We observed high VASH1 density. Supplementary Figure 2L. Negative control slide: the same case with 2J-2K.
Supplementary Methods from EZH2-Regulated DAB2IP Is a Medulloblastoma Tumor Suppressor and a Positive Marker for Survival
Authors: Smits Michiel , van Rijn Sjoerd , Hulleman Esther , Biesmans Dennis , van Vuurden Dannis G. , Kool Marcel , Haberler Christine , Aronica Eleonora , Vandertop W. Peter , Noske David P. , Würdinger Thomas
Published: April 2023

PDF file, 77KB.
Supplementary Figure 2 from Somatic Profiling of the Epidermal Growth Factor Receptor Pathway in Tumors from Patients with Advanced Colorectal Cancer Treated with Chemotherapy ± Cetuximab
Authors: Smith Christopher G. , Fisher David , Claes Bart , Maughan Timothy S. , Idziaszczyk Shelley , Peuteman Gilian , Harris Rebecca , James Michelle D. , Meade Angela , Jasani Bharat , Adams Richard A. , Kenny Sarah , Kaplan Richard , Lambrechts Diether , Cheadle Jeremy P.
Published: April 2023

PDF - 26K, Kaplan-Meier plots of OS and PFS for patients with PIK3CA wild type or mutant tumours.
Supplementary Table 2 from Increased TGF-α as a Mechanism of Acquired Resistance to the Anti-EGFR Inhibitor Cetuximab through EGFR–MET Interaction and Activation of MET Signaling in Colon Cancer Cells
Authors: Troiani Teresa , Martinelli Erika , Napolitano Stefania , Vitagliano Donata , Ciuffreda Loreta Pia , Costantino Sara , Morgillo Floriana , Capasso Anna , Sforza Vincenzo , Nappi Anna , De Palma Raffaele , D'Aiuto Elena , Berrino Liberato , Bianco Roberto , Ciardiello Fortunato
Published: April 2023

PDF file 145K, genes down regulated in GEO-CR versus GEO